Driven somewhat by the HRT controversy and the growing population of postmenopausal women, the expanding osteo market made room for Eli Lilly's Evista (raloxifene), the first-in-class SERM. According to Dr. Leo Plouffe, Lilly's medical director of US women's health and reproductive medicine, the company has launched a series of clinical trials examining Evista's preventive effects against breast cancer and heart disease in women. And in another bold move, Lilly recently launched its groundbreaking Evista Alendronate Comparison (EVA) study, a head-to-head clinical trial comparing Evista with Fosamax for osteoporosis prevention and treatment and their relative efficacy in reducing risks of heart disease and breast cancer.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.